Amneal Pharmaceuticals, Inc. (AMRX) stock
Close on Nov 16, 2026Market cap $6.78BP/E 43.3Yield –
Earnings
Amneal Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Amneal Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 26, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026before the open | $863.00M | +9.9% | -$0.06 | $0.26 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026before the open | $796.00M | +9.8% | $0.18 | $0.30 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $723.00M | +4.0% | $0.19 | $0.27 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 27, 2026before the open | $814.00M | +11.4% | $0.11 | $0.21 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025before the open | $785.00M | +11.8% | $0.01 | $0.17 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $725.00M | – | $0.07 | $0.25 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 2, 2025before the open | $695.00M | +5.5% | $0.04 | $0.21 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 28, 2025before the open | $731.00M | +18.5% | -$0.10 | $0.12 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 8, 2024before the open | $702.00M | +13.2% | $0.00 | $0.16 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 9, 2024before the open | – | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 3, 2024before the open | $659.00M | +18.1% | -$0.30 | $0.14 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 1, 2024before the open | $617.00M | +1.1% | -$0.40 | $0.14 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $620.00M | +13.6% | $0.06 | $0.19 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 4, 2023before the open | $599.00M | +7.2% | $0.08 | $0.19 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 5, 2023before the open | $558.00M | +12.0% | -$0.05 | $0.12 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 2, 2023before the open | $610.00M | +13.6% | -$0.03 | $0.23 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 4, 2022before the open | $546.00M | +3.2% | -$0.02 | $0.14 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 5, 2022before the open | $559.00M | – | -$0.80 | $0.19 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $498.00M | – | -$0.01 | $0.12 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 2, 2022before the open | $537.00M | – | -$0.04 | $0.18 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021before the open | $529.00M | – | -$0.03 | $0.21 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 7, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 26, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 6, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Amneal Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net revenueGAAP | FY2026 | $3.15B – $3.25B | $3.05B – $3.15B | Raised | Nov 3, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $800.00M – $815.00M | $740.00M – $770.00M | Raised | Nov 3, 2026 |
| Adjusted diluted EPSnon-GAAP | FY2026 | $1.04 – $1.08 | $0.95 – $1.05 | Raised | Nov 3, 2026 |
| Capital expenditures | FY2026 | $150.00M | $110.00M | Raised | Nov 3, 2026 |
| Capital expendituresGAAP | FY2026 | $110.00M | – | New | Feb 27, 2026 |
| Operating cash flowGAAP | FY2026 | $325.00M – $375.00M | $350.00M – $400.00M | Lowered | Nov 3, 2026 |
| Operating cash flow, excluding discrete itemsnon-GAAP | FY2026 | $350.00M – $400.00M | $375.00M – $425.00M | Lowered | Nov 3, 2026 |
Guidance vs results
The last range Amneal Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Adjusted diluted EPS | $0.75 – $0.80 | $0.84Σ4Q | Above range |
| FY2025 | Revenue | $3.00B – $3.10B | $3.02BΣ4Q | Within range |
Guidance history
Every forecast Amneal Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | Capital expenditures | FY2026 | $150.00M | Raised |
| Nov 3, 2026 | Adjusted EBITDA | FY2026 | $800.00M – $815.00M | Raised |
| Nov 3, 2026 | Adjusted diluted EPS | FY2026 | $1.04 – $1.08 | Raised |
| Nov 3, 2026 | Operating cash flow | FY2026 | $325.00M – $375.00M | Lowered |
| Nov 3, 2026 | Operating cash flow, excluding discrete items | FY2026 | $350.00M – $400.00M | Lowered |
| Nov 3, 2026 | Net revenue | FY2026 | $3.15B – $3.25B | Raised |
| May 7, 2026 | Capital expenditures | FY2026 | $110.00M | New |
| May 7, 2026 | Adjusted EBITDA | FY2026 | $740.00M – $770.00M | Raised |
| May 7, 2026 | Adjusted diluted EPS | FY2026 | $0.95 – $1.05 | Raised |
| May 7, 2026 | Operating cash flow | FY2026 | $350.00M – $400.00M | Raised |
| May 7, 2026 | Operating cash flow, excluding discrete items | FY2026 | $375.00M – $425.00M | Raised |
| May 7, 2026 | Net revenue | FY2026 | $3.05B – $3.15B | Reaffirmed |
| Feb 27, 2026 | Capital expenditures | FY2026 | $110.00M | New |
| Feb 27, 2026 | Adjusted EBITDA | FY2026 | $720.00M – $760.00M | New |
| Feb 27, 2026 | Adjusted diluted EPS | FY2026 | $0.93 – $1.03 | New |
| Feb 27, 2026 | Operating cash flow | FY2026 | $325.00M – $375.00M | New |
| Feb 27, 2026 | Operating cash flow, excluding discrete items | FY2026 | $350.00M – $400.00M | New |
| Feb 27, 2026 | Net revenue | FY2026 | $3.05B – $3.15B | New |
| Oct 30, 2025 | Capital expenditures | FY2025 | $100.00M | New |
| Oct 30, 2025 | Adjusted EBITDA | FY2025 | $675.00M – $685.00M | New |
| Oct 30, 2025 | Adjusted diluted EPS | FY2025 | $0.75 – $0.80 | New |
| Oct 30, 2025 | Operating cash flow | FY2025 | $300.00M – $330.00M | New |
| Oct 30, 2025 | Operating cash flow, excluding discrete items | FY2025 | $300.00M – $330.00M | New |
| Oct 30, 2025 | Net revenue | FY2025 | $3.00B – $3.10B | New |
| Aug 5, 2025 | Capital expenditures | FY2025 | $100.00M | Reaffirmed |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $665.00M – $685.00M | Raised |
| Aug 5, 2025 | Adjusted diluted EPS | FY2025 | $0.70 – $0.75 | Raised |
| Aug 5, 2025 | Operating cash flow | FY2025 | $275.00M – $305.00M | Raised |
| Aug 5, 2025 | Operating cash flow, excluding discrete items | FY2025 | $300.00M – $330.00M | Raised |
| Aug 5, 2025 | Net revenue | FY2025 | $3.00B – $3.10B | Reaffirmed |
| Feb 28, 2025 | Capital expenditures | FY2025 | $100.00M | New |
| Feb 28, 2025 | Adjusted EBITDA | FY2025 | $650.00M – $675.00M | New |
| Feb 28, 2025 | Adjusted diluted EPS | FY2025 | $0.65 – $0.70 | New |
| Feb 28, 2025 | Operating cash flow | FY2025 | $255.00M – $285.00M | New |
| Feb 28, 2025 | Operating cash flow, excluding discrete items | FY2025 | $280.00M – $310.00M | New |
| Feb 28, 2025 | Net revenue | FY2025 | $3.00B – $3.10B | New |
| May 3, 2024 | Capital expenditures | FY2024 | $60.00M – $70.00M | Reaffirmed |
| May 3, 2024 | Adjusted EBITDA | FY2024 | $580.00M – $620.00M | Reaffirmed |
| May 3, 2024 | Adjusted diluted EPS | FY2024 | $0.53 – $0.63 | Reaffirmed |
| May 3, 2024 | Operating cash flow | FY2024 | $260.00M – $300.00M | Reaffirmed |
| May 3, 2024 | Net revenue | FY2024 | $2.55B – $2.65B | Reaffirmed |
| Mar 1, 2024 | Capital expenditures | FY2024 | $60.00M – $70.00M | New |
| Mar 1, 2024 | Adjusted EBITDA | FY2024 | $580.00M – $620.00M | New |
| Mar 1, 2024 | Adjusted diluted EPS | FY2024 | $0.53 – $0.63 | New |
| Mar 1, 2024 | Operating cash flow | FY2024 | $260.00M – $300.00M | New |
| Mar 1, 2024 | Net revenue | FY2024 | $2.55B – $2.65B | New |
| Nov 7, 2023 | Capital expenditures | FY2023 | $50.00M – $60.00M | Reaffirmed |
| Nov 7, 2023 | Adjusted EBITDA | FY2023 | $540.00M – $550.00M | Reaffirmed |
| Nov 7, 2023 | Adjusted diluted EPS | FY2023 | $0.51 – $0.58 | Reaffirmed |
| Nov 7, 2023 | Weighted average diluted shares outstanding | FY2023 | 310 | Raised |
| Nov 7, 2023 | Operating cash flow | FY2023 | $250.00M – $280.00M | Reaffirmed |
| Nov 7, 2023 | Net revenue | FY2023 | $2.37B – $2.42B | Reaffirmed |
| Oct 23, 2023 | Capital expenditures | FY2023 | $50.00M – $60.00M | Reaffirmed |
| Oct 23, 2023 | Adjusted EBITDA | FY2023 | $540.00M – $550.00M | Raised |
| Oct 23, 2023 | Adjusted diluted EPS | FY2023 | $0.51 – $0.58 | Raised |
| Oct 23, 2023 | Weighted average diluted shares outstanding | FY2023 | 310 | Raised |
| Oct 23, 2023 | Operating cash flow | FY2023 | $250.00M – $280.00M | Raised |
| Oct 23, 2023 | Net revenue | FY2023 | $2.37B – $2.42B | Raised |
| Aug 4, 2023 | Capital expenditures | FY2023 | $50.00M – $60.00M | Reaffirmed |
| Aug 4, 2023 | Adjusted EBITDA | FY2023 | $525.00M – $540.00M | Raised |
| Aug 4, 2023 | Adjusted diluted EPS | FY2023 | $0.45 – $0.55 | Raised |
| Aug 4, 2023 | Weighted average diluted shares outstanding | FY2023 | 307 | Reaffirmed |
| Aug 4, 2023 | Operating cash flow | FY2023 | $220.00M – $250.00M | Raised |
| Aug 4, 2023 | Net revenue | FY2023 | $2.30B – $2.40B | Raised |
| May 5, 2023 | Capital expenditures | FY2023 | $50.00M – $60.00M | Reaffirmed |
| May 5, 2023 | Adjusted EBITDA | FY2023 | $500.00M – $530.00M | Reaffirmed |
| May 5, 2023 | Adjusted diluted EPS | FY2023 | $0.40 – $0.50 | Reaffirmed |
| May 5, 2023 | Weighted average diluted shares outstanding | FY2023 | 307 | New |
| May 5, 2023 | Operating cash flow | FY2023 | $200.00M – $230.00M | Reaffirmed |
| May 5, 2023 | Net revenue | FY2023 | $2.25B – $2.35B | Reaffirmed |
| Apr 17, 2023 | Capital expenditures | FY2023 | $50.00M – $60.00M | New |
| Apr 17, 2023 | Adjusted EBITDA | FY2023 | $500.00M – $530.00M | Reaffirmed |
| Apr 17, 2023 | Adjusted diluted EPS | FY2023 | $0.40 – $0.50 | Reaffirmed |
| Apr 17, 2023 | Weighted average diluted shares outstanding | FY2023 | 307 | Reaffirmed |
| Apr 17, 2023 | Operating cash flow | FY2023 | $200.00M – $230.00M | New |
| Apr 17, 2023 | Net revenue | FY2023 | $2.25B – $2.35B | New |
| Mar 2, 2023 | Capital expenditures | FY2023 | $50.00M – $60.00M | New |
| Mar 2, 2023 | Adjusted EBITDA | FY2023 | $500.00M – $530.00M | New |
| Mar 2, 2023 | Adjusted diluted EPS | FY2023 | $0.40 – $0.50 | New |
| Mar 2, 2023 | Weighted average diluted shares outstanding | FY2023 | 307 | New |
| Mar 2, 2023 | Operating cash flow | FY2023 | $200.00M – $230.00M | New |
| Mar 2, 2023 | Net revenue | FY2023 | $2.25B – $2.35B | New |
| Nov 4, 2022 | Capital expenditures | FY2022 | $65.00M – $75.00M | Lowered |
| Nov 4, 2022 | Adjusted EBITDA | FY2022 | $500.00M – $520.00M | Reaffirmed |
| Nov 4, 2022 | Adjusted diluted EPS | FY2022 | $0.65 – $0.70 | Reaffirmed |
| Nov 4, 2022 | Weighted average diluted shares outstanding | FY2022 | 305 | Lowered |
| Nov 4, 2022 | Operating cash flow | FY2022 | $200.00M – $225.00M | Lowered |
| Nov 4, 2022 | Net revenue | FY2022 | $2.15B – $2.25B | Reaffirmed |
| Aug 5, 2022 | Capital expenditures | FY2022 | $65.00M – $75.00M | Lowered |
| Aug 5, 2022 | Adjusted EBITDA | FY2022 | $500.00M – $520.00M | Lowered |
| Aug 5, 2022 | Adjusted diluted EPS | FY2022 | $0.65 – $0.70 | Lowered |
| Aug 5, 2022 | Weighted average diluted shares outstanding | FY2022 | 305 | New |
| Aug 5, 2022 | Operating cash flow | FY2022 | $200.00M – $225.00M | Lowered |
| Aug 5, 2022 | Net revenue | FY2022 | $2.15B – $2.25B | Reaffirmed |
| May 4, 2022 | Capital expenditures | FY2022 | $75.00M – $85.00M | New |
| May 4, 2022 | Adjusted EBITDA | FY2022 | $540.00M – $560.00M | Reaffirmed |
| May 4, 2022 | Adjusted diluted EPS | FY2022 | $0.80 – $0.85 | Reaffirmed |
| May 4, 2022 | Weighted average diluted shares outstanding | FY2022 | 307 | Reaffirmed |
| May 4, 2022 | Operating cash flow | FY2022 | $225.00M – $250.00M | New |
| May 4, 2022 | Net revenue | FY2022 | $2.15B – $2.25B | New |
| Mar 2, 2022 | Capital expenditures | FY2022 | $75.00M – $85.00M | New |
| Mar 2, 2022 | Adjusted EBITDA | FY2022 | $540.00M – $560.00M | New |
| Mar 2, 2022 | Adjusted diluted EPS | FY2022 | $0.80 – $0.85 | New |
| Mar 2, 2022 | Weighted average diluted shares outstanding | FY2022 | 307 | New |
| Mar 2, 2022 | Operating cash flow | FY2022 | $225.00M – $250.00M | New |
| Mar 2, 2022 | Net revenue | FY2022 | $2.15B – $2.25B | New |
| Nov 3, 2021 | Capital expenditures | FY2021 | $50.00M – $60.00M | New |
| Nov 3, 2021 | Adjusted EBITDA | FY2021 | $530.00M – $550.00M | New |
| Nov 3, 2021 | Adjusted diluted EPS | FY2021 | $0.78 – $0.88 | New |
| Nov 3, 2021 | Weighted average diluted shares outstanding | FY2021 | 304 | New |
| Nov 3, 2021 | Operating cash flow | FY2021 | $220.00M – $250.00M | New |
| Nov 3, 2021 | Net revenue | FY2021 | $2.10B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Amneal Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Update
See a number that looks wrong?